Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis

BACKGROUND: The differences in progression-free survival (PFS) and cancer-specific survival (CSS) of metastatic renal cell carcinoma (mRCC) patients according to treatment, type of metastasis, and Heng criteria risk are unclear. In this study, we compared survival according to various such parameter...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Sung Han, Lee, Dong-eun, Park, Boram, Joo, Jungnam, Joung, Jae Young, Seo, Ho Kyung, Lee, Kang Hyun, Chung, Jinsoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631605/
https://www.ncbi.nlm.nih.gov/pubmed/31307432
http://dx.doi.org/10.1186/s12885-019-5900-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631605/
https://www.ncbi.nlm.nih.gov/pubmed/31307432
http://dx.doi.org/10.1186/s12885-019-5900-1

Ejemplares similares